📊 ABT Key Takeaways
Is Abbott Laboratories (ABT) a Good Investment?
Abbott demonstrates solid fundamental strength with robust profitability metrics (14.7% net margin, 18.2% operating margin) and excellent cash generation (7.4B free cash flow, 16.7% FCF margin). The company maintains a fortress balance sheet with conservative leverage (0.25x debt/equity) and exceptional interest coverage (57.1x), positioning it well for reinvestment and shareholder returns. However, growth has decelerated significantly with net income up only 0.4% YoY despite 5.7% revenue growth, warranting careful monitoring of margin sustainability.
Abbott Laboratories shows solid fundamental quality, with mid-single-digit revenue growth, strong operating profitability, and robust free cash flow generation. The balance sheet appears conservative, with low leverage, ample liquidity, and very high interest coverage, which supports resilience and flexibility. The main caveat is mixed earnings quality, as diluted EPS fell sharply despite stable net income, suggesting non-operating or capital structure effects that warrant closer scrutiny.
Why Buy Abbott Laboratories Stock? ABT Key Strengths
- Exceptional cash generation with 7.4B annual free cash flow and 16.7% FCF margin demonstrates operational efficiency
- Conservative capital structure with 0.25x debt/equity ratio and 57.1x interest coverage provides financial flexibility
- Solid profitability metrics with 14.7% net margin and 18.2% operating margin are healthy for pharmaceutical sector
- Strong liquidity position with 1.58x current ratio and 8.5B cash enabling strategic flexibility
- Consistent top-line growth with revenue up 5.7% year over year
- Strong financial health supported by low debt-to-equity, solid liquidity, and 57.1x interest coverage
- Healthy cash generation with $7.39B of free cash flow and a 16.7% free cash flow margin
ABT Stock Risks: Abbott Laboratories Investment Risks
- Net income growth has essentially stalled at 0.4% YoY despite 5.7% revenue growth, signaling margin compression or operational headwinds
- Gross margin of only 9.9% is unusually low and warrants investigation into cost structure or product mix deterioration
- Significant diluted EPS decline of 51.3% YoY suggests material increase in share count or one-time charges that requires clarification
- ROE of 12.5% and ROA of 7.5% are modest, indicating capital may not be deployed with optimal efficiency
- Diluted EPS declined 51.3% year over year despite flat net income, indicating potential earnings quality or one-time distortions
- Net income growth of just 0.4% trails revenue growth, suggesting margin pressure or higher costs below the operating line
- Reported gross margin appears unusually low relative to the business profile, raising possible data classification or reporting-quality concerns
Key Metrics to Watch
- Net income and operating margin trend - critical given YoY growth deceleration despite revenue gains
- Gross margin sustainability - 9.9% is concerning and needs explanation for sector context
- Free cash flow conversion and capital allocation strategy - verify cash generation continues to fund growth and returns
- Share dilution trend - investigate drivers behind 51.3% EPS decline to assess shareholder value erosion
- Operating margin and net margin progression
- Free cash flow conversion relative to net income
Abbott Laboratories (ABT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Abbott Laboratories presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ABT Profit Margin, ROE & Profitability Analysis
ABT vs Healthcare Sector: How Abbott Laboratories Compares
How Abbott Laboratories compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Abbott Laboratories Stock Overvalued? ABT Valuation Analysis 2026
Based on fundamental analysis, Abbott Laboratories has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Abbott Laboratories Balance Sheet: ABT Debt, Cash & Liquidity
ABT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Abbott Laboratories's revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $3.26 reflects profitable operations.
ABT Revenue Growth, EPS Growth & YoY Performance
ABT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.6B | $1.6B | $0.94 |
| Q2 2025 | $10.4B | $1.3B | $0.74 |
| Q1 2025 | $10.0B | $1.2B | $0.70 |
| Q3 2024 | $10.1B | $1.4B | $0.82 |
| Q2 2024 | $10.0B | $1.3B | $0.74 |
| Q1 2024 | $9.7B | $1.2B | $0.70 |
| Q3 2023 | $10.1B | $1.4B | $0.81 |
| Q2 2023 | $10.0B | $1.4B | $0.78 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Abbott Laboratories Dividends, Buybacks & Capital Allocation
ABT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Abbott Laboratories (CIK: 0000001800)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090447.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090414.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090438.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090418.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090445.xml | View → |
❓ Frequently Asked Questions about ABT
What is the AI rating for ABT?
Abbott Laboratories (ABT) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABT's key strengths?
Claude: Exceptional cash generation with 7.4B annual free cash flow and 16.7% FCF margin demonstrates operational efficiency. Conservative capital structure with 0.25x debt/equity ratio and 57.1x interest coverage provides financial flexibility. ChatGPT: Consistent top-line growth with revenue up 5.7% year over year. Strong financial health supported by low debt-to-equity, solid liquidity, and 57.1x interest coverage.
What are the risks of investing in ABT?
Claude: Net income growth has essentially stalled at 0.4% YoY despite 5.7% revenue growth, signaling margin compression or operational headwinds. Gross margin of only 9.9% is unusually low and warrants investigation into cost structure or product mix deterioration. ChatGPT: Diluted EPS declined 51.3% year over year despite flat net income, indicating potential earnings quality or one-time distortions. Net income growth of just 0.4% trails revenue growth, suggesting margin pressure or higher costs below the operating line.
What is ABT's revenue and growth?
Abbott Laboratories reported revenue of $44.3B.
Does ABT pay dividends?
Abbott Laboratories pays dividends, with $4,116.0M distributed to shareholders in the trailing twelve months.
Where can I find ABT SEC filings?
Official SEC filings for Abbott Laboratories (CIK: 0000001800) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABT's EPS?
Abbott Laboratories has a diluted EPS of $3.72.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ABT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Abbott Laboratories has a BUY rating with 77% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ABT stock overvalued or undervalued?
Valuation metrics for ABT: ROE of 12.5% (sector avg: 15%), net margin of 14.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ABT stock in 2026?
Our dual AI analysis gives Abbott Laboratories a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ABT's free cash flow?
Abbott Laboratories's operating cash flow is $9.6B, with capital expenditures of $2.2B. FCF margin is 16.7%.
How does ABT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 14.7% (avg: 12%), ROE 12.5% (avg: 15%), current ratio 1.58 (avg: 2).